The role of miR-129-5p in cancer: a novel therapeutic target

2021 ◽  
Vol 14 ◽  
Author(s):  
Shan Xu ◽  
Wei Li ◽  
Jing Wu ◽  
Yuru Lu ◽  
Ming Xie ◽  
...  
Keyword(s):  
Human Body ◽  
Targeted Therapies ◽  
Therapeutic Target ◽  
Malignant Tumors ◽  
Biological Functions ◽  
Abnormal Expression ◽  
Wide Range ◽  
Novel Therapeutic

: MiRNA-129-5p belongs to the microRNA-129 (miRNA-129) family. MiRNA-129-5p is expressed in many tissues and organs of the human body, and it regulates a wide range of biological functions. The abnormal expression of miRNA-129-5p is related to the occurrence and development of a variety of malignant tumors. MiRNA-129-5p plays an important role in the tumorigenesis process and functions by promoting or inhibiting tumors. However, the role of miRNA-129-5p in cancer remains controversial. This article reviews the different biological functions of miRNA-129-5p in cancer and provides ideas for research in this field to guide the development of targeted therapies and drugs for malignant tumors.

Characterization of proteins with Siaα2-3/6Gal-linked glycans from bovine milk and role of their glycans against influenza A virus

2018 ◽  
Vol 9 (10) ◽  
pp. 5198-5208 ◽  
Author(s):  
Hanjie Yu ◽  
Yaogang Zhong ◽  
Zhiwei Zhang ◽  
Xiawei Liu ◽  
Kun Zhang ◽  
...  
Keyword(s):  
Influenza A Virus ◽  
Influenza A ◽  
Bovine Milk ◽  
Milk Proteins ◽  
Biological Functions ◽  
Wide Range ◽  
Range Of Functions ◽  
Bovine Milk Proteins

The bovine milk proteins have a wide range of functions, but the role of the attached glycans in their biological functions has not been fully understood yet.

Molecular Interactions of α-Synuclein, Mitochondria, and Cellular Degradation Pathways in Parkinson's Disease

2020 ◽  
pp. 212-234
Author(s):  
Mansi Verma ◽  
Sujata Basu ◽  
Manisha Singh ◽  
Rachana R. ◽  
Simrat Kaur ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Molecular Interactions ◽  
Therapeutic Target ◽  
Molecular Mechanisms ◽  
Degradation Pathways ◽  
Functional Changes ◽  
The World ◽  
Novel Therapeutic

Parkinson's disease (PD) has been reported to be the most common neurodegenerative diseases all over the world. Several proteins are associated and responsible for causing PD. One such protein is α-synuclein. This chapter discusses the role of α-synuclein in PD. Various genetic and epigenetic factors, which cause structural and functional changes for α-synuclein, have been described. Several molecular mechanisms, which are involved in regulating mitochondrial and lysosomal related pathways and are linked to α-synuclein, have been discussed in detail. The knowledge gathered is further discussed in terms of using α-synuclein as a diagnostic marker for PD and as a novel therapeutic target for the same.

scholarly journals Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target

2019 ◽  
Vol 19 (1) ◽  
pp. 187-198 ◽  
Author(s):  
Toshihiro Kushibiki ◽  
Toru Nakamura ◽  
Masumi Tsuda ◽  
Takahiro Tsuchikawa ◽  
Koji Hontani ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Therapeutic Target ◽  
Novel Therapeutic

scholarly journals The Role of DLLs in Cancer: A Novel Therapeutic Target

2020 ◽  
Vol Volume 13 ◽  
pp. 3881-3901 ◽  
Author(s):  
Meng-Xi Xiu ◽  
Yuan-Meng Liu ◽  
Bo-hai Kuang
Keyword(s):  
Therapeutic Target ◽  
Novel Therapeutic

Update on the role of autophagy in systemic lupus erythematosus: A novel therapeutic target

2015 ◽  
Vol 71 ◽  
pp. 190-193 ◽  
Author(s):  
Qingjun Pan ◽  
Caina Gao ◽  
Yanwen Chen ◽  
Yongmin Feng ◽  
Wei Jing Liu ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Therapeutic Target ◽  
Systemic Lupus ◽  
Novel Therapeutic

scholarly journals The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Quan Dong Nguyen ◽  
Jeffrey S. Heier ◽  
Diana V. Do ◽  
Adam C. Mirando ◽  
Niranjan B. Pandey ◽  
...  
Keyword(s):  
Macular Edema ◽  
Vascular Permeability ◽  
Signaling Pathway ◽  
Therapeutic Target ◽  
Vascular Diseases ◽  
Age Related Macular Degeneration ◽  
Vegf Receptor ◽  
Therapeutic Benefits ◽  
Novel Therapeutic

Abstract Background Retinal vascular diseases such as neovascular age-related macular degeneration, diabetic retinopathy and/or diabetic macular edema, and retinal vein occlusion with macular edema—share several key pathophysiologic aspects including neovascularization, vascular permeability, and inflammation. The role of vascular endothelial growth factor (VEGF) in these processes, and the therapeutic benefits of VEGF inhibition, have been well characterized. Anti-VEGF therapy is highly effective for many patients but is not uniformly effective in all patients and imposes a significant treatment burden. More recently, the role of the Tie2 signaling pathway in the pathophysiology of retinal vascular diseases has been investigated, and the Tie2 pathway represents a novel therapeutic target for these conditions. Areas covered The index review describes the Tie2 pathway and its complementary role to the VEGF pathway in the angiogenesis cascade and will summarize studies of molecules in development to therapeutically modulate the Tie2 pathway in retinal vascular diseases. Conclusions Activation of the Tie2 pathway leads to downstream signaling that promotes vascular health and stability and decreases vascular permeability and inflammation. AXT107 is a collagen IV–derived synthetic peptide with a dual mechanism of action that involves suppression of VEGF signaling and activation of the Tie2 pathway; these actions are accomplished by AXT107 binding to and disrupting different integrin, leading to blockade of the VEGF receptor and rearrangement of cellular Tie2 rendering it susceptible to Ang2 agonism. Other Tie2 agonist compounds are also in development, including faricimab and razuprotafib. Tie2 activation only modestly impacts angiogenesis on its own but significantly potentiates VEGF suppression. Co-regulation of the VEGF and Tie2 signaling pathways has the potential to improve functional and structural outcomes in eyes with retinal vascular diseases.

scholarly journals Emerging Role of the NLRP3 Inflammasome and Interleukin-1β in Neonates

Neonatology ◽  
2020 ◽  
pp. 1-10
Author(s):  
Murwan Omer ◽  
Ashanty Maggvie Melo ◽  
Lynne Kelly ◽  
Emma Jane Mac Dermott ◽  
Timothy Ronan Leahy ◽  
...  
Keyword(s):  
Cerebral Palsy ◽  
Nlrp3 Inflammasome ◽  
Therapeutic Target ◽  
Inflammasome Activation ◽  
Neonatal Brain ◽  
Persistent Inflammation ◽  
Attractive Therapeutic Target ◽  
Clinical Models ◽  
Novel Therapeutic

Infection and persistent inflammation have a prominent role in the pathogenesis of brain injury and cerebral palsy, as well as other conditions associated with prematurity such as bronchopulmonary dysplasia. The NLRP3 inflammasome-interleukin (IL)-1β pathway has been extensively studied in adults and pre-clinical models, improving our understanding of innate immunity and offering an attractive therapeutic target that is already contributing to clinical management in many auto-inflammatory disorders. IL-1 blockade has transformed the course and outcome of conditions such as chronic infantile neurological, cutaneous, articular (CINCA/NOMID) syndrome. Inflammasome activation and upregulation has recently been implicated in neonatal brain and lung inflammatory disease and may be a novel therapeutic target.

Sign in / Sign up

Export Citation Format

Share Document